Pipeline
Early Discovery
- (WO)
Oncology
- (WO)
Oncology
- (WO)
Oncology
- (WO)
Oncology
- (CO)
Oncology
PARP1(EQRx) - (CO)
Oncology
(GTA) - (CO)
Oncology
(Huandong) - (PP)
Oncology
(BMS) - (PP)
Oncology
(BMS) - (PP)
Oncology
(BMS) - (PP)
Oncology
(Sanofi) - (PP)
Oncology
(Sanofi) - (CO)
Inflammation & Immunity
(EQRx) - (CO)
Inflammation & Immunity
(EQRx) - (PP)
Inflammation & Immunity
(BMS) - (PP)
Inflammation & Immunity
(BMS) - (PP)
Inflammation & Immunity
Bispecific Small Molecule(Sanofi) - (PP)
Inflammation & Immunity
(Sanofi) - (WO)
Anti-infective
(Gates)
Late Discovery
- (CO)
Oncology
ENPP1(Rallybio) - (WO)
Inflammation & Immunity
NLRP3 - (WO)
Coronavirus
M pro(Gates) - (CO)
HPP
ENPP1(Rallybio) - (CO)
Psychiatry
(Blue Oak)
Ind-Enabling
- (WO)
Oncology
MALT1(EXS73565) - (WO)
Oncology
LSD1(EXS74539)
Phase 1 / 2
- (Pilot)
High Adenosine Signature Cancers
A2A(EXS21546) - (CO)
Transcriptionally Addicted Cancers
CDK7(GTAEXS617) (GTA) - (PP)
Inflammatory Diseases
PKC-theta(EXS4318) (BMS)*
* Phase 1
(WO) = Wholly Owned
(CO) = Co-owned
(PP) = Pharma Partnership
Does not include Exscientia-designed programmes that entered clinical trials through DSP collaboration